Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Views & Analysis Mind the (implementation) gap Examining the true impact of a positive health technology assessment (HTA).
Views & Analysis Navigating the barriers to successful market access The steps required for successful market access.
Views & Analysis Keeping ahead of the curve Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
Views & Analysis PRIME movers: taking stock of the EMA's scheme Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
Views & Analysis What is ‘affordable’? The reality of the PPRS PPRS impact: has it kept the branded medicines bill within affordable limits?
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
